Racura Oncology Ltd

As of June 30, 2026, Racura Oncology Ltd carries a market capitalization of 435.27M, placing it among publicly traded companies globally. Its enterprise value stands at 400.98M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Racura Oncology Ltd's next confirmed earnings release is scheduled for March 3, 2027.

As of June 30, 2026, Racura Oncology Ltd has 196.07M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Racura Oncology Ltd maintains a current ratio of 21.43, meaning it holds 21.4x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Racura Oncology Ltd posted a negative return on equity (ROE) of -42.28, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -39.90, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Racura Oncology Ltd's stock has declined approximately 59.27% over the past 52 weeks. The 50-day moving average sits at 1.96, while the 200-day moving average is 2.32.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -13.09M, while operating income came in at -13.37M.

These figures are as of June 30, 2026. Total book value stands at 36.45M, with working capital of 33.00M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -6.63, meaning Racura Oncology Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.